Jo Hae Park
Head of BD TriOar Biotechnology
Dr. Jo Hae Park is Head of Business Development at TriOar Inc, specializing in ADC technology licensing and platform partnerships. She previously in-licensed ADC technology from Synaffix at Chong Kun Dang and led the CKD-703 ADC program through preclinical development and global partnering. She also orchestrated the landmark $1.305B out-licensing deal with Novartis for CKD-510. She served as Director at Intervest, managing investments in ADC-focused biotech companies and conducted comprehensive market analyses across the ADC landscape. Dr. Park holds a Ph.D. in Molecular and Cellular Biology from Seoul National University and a B.S. from Emory University.
Seminars
Tuesday 9th June 2026
From Concept to Modality: Five Years That Have Reshaped the ADC Landscape
9:00 am
- Summary of the advancement in the last five years: Explore how ADCs have evolved into platform innovations, mirrored by surge in strategic global licensing and mergers and acquisitions
- Key ADC success driving the field: Discuss the clinical results that have reinforced therapeutic index and tumor biology -not potency alone-, driving success and deal value
- Industry shaping: Discover how large pharma will scale and commercialize ADCs, while small biotechs will continue to fuel platform and early-stage innovation
